LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China

LEO Pharma knows it’s in for a brawl with powerful players in atopic dermatitis. With some positive Phase III data in and regulatory filings on the way, the Danish drugmaker is shelling out $40 million upfront on a new drug candidate that goes at both eczema and asthma from a different angle.